As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why. Short-selling firm Hindenburg ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.